Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesc Bosch

Showing results (111-120 of 170) with videos related to

Pageof 17
Sort By:
Haematologica|February 22, 2020
Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomasSabela Bobillo, Marta Crespo, Laura Escudero, et al.
Experimental Hematology|January 9, 2021
Chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemiaGonzalo Blanco, Anna Puiggros, Barbara Sherry, et al.
Blood|September 21, 2006
Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlationsKostas Stamatopoulos, Chrysoula Belessi, Carol Moreno, et al.
British Journal of Haematology|July 27, 2025
A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trialCecilia Carpio, Fátima de la Cruz-Vicente, Ramon García-Sanz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2021
Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin LymphomaMarcelo Lima Ribeiro, Diana Reyes-Garau, Meritxell Vinyoles, et al.
British Journal of Haematology|January 23, 2026
Exploring the synergy between telomere length and genomic complexity in CLLSilvia Ramos-Campoy, Anna Puiggros, Joanna Kamaso, et al.
Blood Advances|June 10, 2026
Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphomaMario Andrés Sánchez-Salinas, Javier Varela-Gonzalez-Aller, Gloria Iacoboni, et al.
Blood Advances|April 9, 2026
Performance and Clinical Utility of Spanish Germline Genetic Testing Criteria for Hematologic Neoplasms PredispositionSara Torres-Esquius, Guillermo Ramil, Maria Gabarrós-Subirà, et al.
Blood Advances|May 22, 2025
Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disordersÁngel Serna, Víctor Navarro, Moraima Jimenez, et al.
Leukemia & Lymphoma|July 14, 2020
Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxisMaría Laura Fox, Irene García-Cadenas, Ariadna Martínez Pérez, et al.
Pageof 17

Showing results (111-120 of 170) with videos related to

Sort By:
Pageof 17
Haematologica|February 22, 2020
Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomasSabela Bobillo, Marta Crespo, Laura Escudero, et al.
Experimental Hematology|January 9, 2021
Chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemiaGonzalo Blanco, Anna Puiggros, Barbara Sherry, et al.
Blood|September 21, 2006
Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlationsKostas Stamatopoulos, Chrysoula Belessi, Carol Moreno, et al.
British Journal of Haematology|July 27, 2025
A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trialCecilia Carpio, Fátima de la Cruz-Vicente, Ramon García-Sanz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2021
Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin LymphomaMarcelo Lima Ribeiro, Diana Reyes-Garau, Meritxell Vinyoles, et al.
British Journal of Haematology|January 23, 2026
Exploring the synergy between telomere length and genomic complexity in CLLSilvia Ramos-Campoy, Anna Puiggros, Joanna Kamaso, et al.
Blood Advances|June 10, 2026
Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphomaMario Andrés Sánchez-Salinas, Javier Varela-Gonzalez-Aller, Gloria Iacoboni, et al.
Blood Advances|April 9, 2026
Performance and Clinical Utility of Spanish Germline Genetic Testing Criteria for Hematologic Neoplasms PredispositionSara Torres-Esquius, Guillermo Ramil, Maria Gabarrós-Subirà, et al.
Blood Advances|May 22, 2025
Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disordersÁngel Serna, Víctor Navarro, Moraima Jimenez, et al.
Leukemia & Lymphoma|July 14, 2020
Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxisMaría Laura Fox, Irene García-Cadenas, Ariadna Martínez Pérez, et al.
Pageof 17